Company: IMCR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001671927-25-000014
Chunk: 26

Company: Immunocore Holdings plc
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
 30,2025202420252024Convertible senior notesCoupon interest$2,515 $2,480 $5,031 $4,107 Amortization of debt issuance costs530 513 1,039 832 Pharmakon loan — 1,284 — 2,577 Total interest expense$3,045 $4,277 $6,070 $7,516 

6. Share-based compensation

The following table shows the total share-based compensation expense recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (in thousands):Three Months Ended June 30,Six Months Ended June 30,2025202420252024Research and development$2,318 $2,172 $4,499 $4,152 Selling, general and administrative $7,715 $7,828 $15,023 $14,812 

11

Table of Contents

Equity Incentive PlanUnder the Company’s Equity Incentive Plan ("EIP"), the Company may grant market value options, share appreciation rights or restricted shares, restricted share units ("RSUs"), performance share units and other share-based awards to the Company’s employees. The Company’s board members and consultants are eligible to receive awards under the Company’s non-employee sub-plan to the EIP. Awards may be granted at such times as the Company may determine, but will generally be granted annually following the end of the financial year. Awards vest at such times and as specified in the award agreement, typically being over a four-year period, although the Company retains the discretion to provide for other vesting schedules. If the participant violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions of any employment contract, the right of the participant to receive these shares on vesting shall terminate immediately. The Company maintains discretion over the type and terms of equity awards granted. Share options lapse on the tenth anniversary from the date of grant, and they are not subject to performance conditions or entitled to dividends. As of June 30, 2025, the Company has reserved 6,139,943 authorized shares for future issuance under the EIP. Share option activityThe number and weighted average exercise prices of share options were as follows:Number of  Share OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual TermAggregate Intrinsic Value (in thousands)Outstanding as of December 31, 20249,